Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial

Filgotinib was well-tolerated over 52 weeks with no serious adverse events reported. Numerical changes in disease activity markers were observed over time, providing preliminary support for the therapeutic concept of JAK inhibition in iMCD.

Authors

Institutions

Publication Details

Journal
Modern Rheumatology
Published
2026-02-18
DOI
https://doi.org/10.1093/mr/roag011
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial

T. Koga, Rieko Kiya, Sawana Narita, A. Kawamoto et al.
Modern Rheumatology
Viral-associated cancers and disorders
article

Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial

T. Koga, Rieko Kiya, Sawana Narita, A. Kawamoto, Kayako Matsuyama, Remi Sumiyoshi, Atsushi Katsube, Osamu Kamisawa, Naoki Kato, Naoki Hosogaya, Shoichi Fukui, Shingo Yano, Atsushi Kawakami
article en

Abstract

Filgotinib was well-tolerated over 52 weeks with no serious adverse events reported. Numerical changes in disease activity markers were observed over time, providing preliminary support for the therapeutic concept of JAK inhibition in iMCD.

Modern Rheumatology
Jikei University School of Medicine (JP), Foundation for Biomedical Research (US), Nagasaki University Hospital (JP), Foundation for Biomedical Research and Innovation (JP), Nagasaki University (JP)
Good health and well-being
Openalex Percentile: Top 48%
Viral-associated cancers and disorders
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial — T. Koga, Rieko Kiya, et al. · Modern Rheumatology (2026) | TGRS Research Map | TGRS